154 related articles for article (PubMed ID: 24759403)
21. Perspective: Retreat from the radical.
Marder SR
Nature; 2014 Apr; 508(7494):S18. PubMed ID: 24695331
[No Abstract] [Full Text] [Related]
22. [Reelin dysfunction in neuropsychiatric diseases and its potential as a drug target].
Hattori M
Nihon Yakurigaku Zasshi; 2012 Mar; 139(3):99-102. PubMed ID: 22451463
[No Abstract] [Full Text] [Related]
23. Help luck along to find psychiatric medicines.
Nutt D
Nature; 2014 Nov; 515(7526):165. PubMed ID: 25391924
[No Abstract] [Full Text] [Related]
24. Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology.
Waddington JL
Gen Pharmacol; 1988; 19(1):55-60. PubMed ID: 3278946
[No Abstract] [Full Text] [Related]
25. [The chronobiological approach--a way to enhance the efficacy of pharmacotherapy in neurology and psychiatry].
Arushanian EB
Eksp Klin Farmakol; 1992; 55(4):67-9. PubMed ID: 1458197
[No Abstract] [Full Text] [Related]
26. [Between psyche and brain : State of the art in psychiatry].
Fuchs T
Nervenarzt; 2017 May; 88(5):520-528. PubMed ID: 28324134
[TBL] [Abstract][Full Text] [Related]
27. [Clinical trials in psychiatry: present status and prospects].
Azorin JM; Belzeaux R; Adida M
Encephale; 2016 Dec; 42(6S):S1. PubMed ID: 28236985
[No Abstract] [Full Text] [Related]
28. Medicine. A boost for translational neuroscience.
Ehrenreich H
Science; 2004 Jul; 305(5681):184-5. PubMed ID: 15247460
[No Abstract] [Full Text] [Related]
29. Use of beta-blocking drugs in psychiatry and neurology.
Tyrer PJ
Drugs; 1980 Oct; 20(4):300-8. PubMed ID: 6106546
[No Abstract] [Full Text] [Related]
30. [Controlled clinical study and clinico-psychological evaluation of a preparation with neurotrophic effects].
Montini M; Ongaro A; Simonutti M
Clin Ter; 1977 Aug; 82(3):243-62. PubMed ID: 334449
[No Abstract] [Full Text] [Related]
31. The National Institute of Mental Health Research Domain Criteria and Clinical Research in Child and Adolescent Psychiatry.
Garvey M; Avenevoli S; Anderson K
J Am Acad Child Adolesc Psychiatry; 2016 Feb; 55(2):93-8. PubMed ID: 26802775
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.
Deepmala ; Slattery J; Kumar N; Delhey L; Berk M; Dean O; Spielholz C; Frye R
Neurosci Biobehav Rev; 2015 Aug; 55():294-321. PubMed ID: 25957927
[TBL] [Abstract][Full Text] [Related]
33. Beta-adrenoceptor antagonists in psychiatry and neurology.
Middlemiss DN; Buxton DA; Greenwood DT
Pharmacol Ther; 1981; 12(2):419-37. PubMed ID: 6112765
[No Abstract] [Full Text] [Related]
34. [The pharmacological properties of calcium channel blockers and the outlook for their use in psychiatry and neurology].
Kozlovskiĭ VL
Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(1):104-8. PubMed ID: 8009924
[No Abstract] [Full Text] [Related]
35. Placebo effects: from the neurobiological paradigm to translational implications.
Benedetti F
Neuron; 2014 Nov; 84(3):623-37. PubMed ID: 25442940
[TBL] [Abstract][Full Text] [Related]
36. Methods of multicenter trials in psychiatry. Part I: Review.
Fischer-Cornelssen KA
Prog Neuropsychopharmacol; 1980; 4(6):545-60. PubMed ID: 7220670
[No Abstract] [Full Text] [Related]
37. Diagnosis-related groups and clinical research in psychiatry.
Pincus HA; West J; Goldman H
Arch Gen Psychiatry; 1985 Jun; 42(6):627-9. PubMed ID: 2988478
[No Abstract] [Full Text] [Related]
38. Targeting voltage-gated calcium channels in neurological and psychiatric diseases.
Zamponi GW
Nat Rev Drug Discov; 2016 Jan; 15(1):19-34. PubMed ID: 26542451
[TBL] [Abstract][Full Text] [Related]
39. NIMH to screen studies for science and human risks.
Marshall E
Science; 1999 Jan; 283(5401):464-5. PubMed ID: 9988644
[No Abstract] [Full Text] [Related]
40. Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.
Moran SP; Maksymetz J; Conn PJ
Trends Pharmacol Sci; 2019 Dec; 40(12):1006-1020. PubMed ID: 31711626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
